Korro Bio Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
KRRO$15.73+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(amounts in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Operating expenses: | ||||
| Research and development | $15,964 | $14,008 | $46,674 | $41,828 |
| General and administrative | 7,328 | 5,140 | 22,196 | 15,813 |
| Total operating expenses | 23,292 | 19,148 | 68,870 | 57,641 |
| Loss from operations | (23,292) | (19,148) | (68,870) | (57,641) |
| Other income: | ||||
| Other income, net | 2,284 | 656 | 6,526 | 1,922 |
| Total other income, net | 2,284 | 656 | 6,526 | 1,922 |
| Loss before provision for income taxes | (21,008) | (18,492) | (62,344) | (55,719) |
| Provision for income taxes | 9 | - | (38) | (27) |
| Net loss | $(20,999) | $(18,492) | $(62,382) | $(55,746) |
| Other comprehensive income: | ||||
| Unrealized gain on available-for-sale marketable securities | $593 | $— | $614 | $5 |
| Foreign currency translation adjustments, net | $(40) | $— | $(40) | $— |
| Comprehensive loss | $(20,446) | $(18,492) | $(61,808) | $(55,741) |
| Net loss per share, basic and diluted | $(2.26) | $(65.08) | $(7.11) | $(200.94) |
| Weighted-average shares used in computing net loss per share, basic and diluted | 9,303,218 | 284,156 | 8,771,743 | 277,433 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.